Craig-Hallum raised the firm’s price target on Curaleaf to $3.50 from $2.75 and keeps a Hold rating on the shares. The firm is encouraged that margin expansion remains ahead of management’s expectations thus far in Q1 and by the growth expected in Europe but would like to gain more confidence in the relative margin, cash flow and liquidity outlook and/or a more attractive valuation before upgrading shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CURLF:
- Curaleaf Posts Solid Year-End Growth
- Curaleaf Reports Fourth Quarter and Full Year Ended 2023 Results
- Curaleaf Holdings (OTC) (CURLF) Q4 Earnings Cheat Sheet
- Curaleaf price target raised to $7 from $4 at Roth MKM
- Curaleaf International Acquires Can4Med, Expanding Presence in Poland’s Growing Medical Cannabis Market